Amgen Inc (AMGN)

pos +0.00
Today's Range: 172.48 - 174.72 | AMGN Avg Daily Volume: 3,598,700
Last Update: 02/24/17 - 4:00 PM EST
Volume: 0
YTD Performance: 19.01%
Open: $0.00
Previous Close: $174.01
52 Week Range: $133.64 - $176.85
Oustanding Shares: 736,452,791
Market Cap: 128,150,150,162
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 4 4
Moderate Buy 1 1 1 1
Hold 9 10 11 11
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.16 2.28 2.41 2.41
Latest Dividend: 1.15
Latest Dividend Yield: 2.64%
Dividend Ex-Date: 02/13/17
Price Earnings Ratio: 16.99
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
16.99 17.00 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.98% 18.54% 40.50%
Revenue 6.10 0.20 0.07
Net Income 11.30 0.50 0.15
EPS 13.00 0.50 0.15
Earnings for AMGN:
Revenue 22.99B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $2.99 $3.10 $12.27 $12.81
Number of Analysts 9 8 12 9
High Estimate $3.11 $3.36 $12.95 $13.73
Low Estimate $2.80 $2.90 $11.81 $12.39
Prior Year $2.90 $2.84 $11.65 $12.27
Growth Rate (Year over Year) 3.14% 9.02% 5.36% 4.39%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Feb 22, 2017 | 7:24 AM EST
AMGN estimates were raised through 2018, Oppenheimer said. New product approvals and label expansion filings should drive growth. Outpe...

Amgen Shows a Bullish Breakout Real Money Pro($)

There is more upside to come for this stock.
You might want to review your holdings in the sector.
Some tried-and-true indicators show what's really going on with the market.
Feb 13, 2017 | 7:28 AM EST
AMGN now seen reaching $212, according to BMO Capital. Estimates also raised, following positive physician and payor feedback. Outperfo...
Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie Real Money Pro($)

Getting FDA to streamline its approval process would boost drug makers.
The Fed is simply not a market catalyst this time.
There's not much reason to be bullish on these stocks.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

Columnist Conversations

One of the fundamental concepts of market characteristics is they generally don't go straight up or straight d...
With less than an hour left in the session COP is trading below its January low. This key support area($47.20)...
tremendous flow here today and a big reversal candle. BOUGHT LB MAY 50 CALL AT 3.80 Poor reaction pos...
We have a nice gainer here, let's unload it SOLD OLED MAR 75 CALL AT 6.40 (in at 2.70)


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.